As of the most recent data (June 2026), GE9.F shows a EBIT of $2.7B. That compares with $4.7B in the prior-year period — down 42.9% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GE9.F's EBIT is now $2.7B (was $4.7B) — a 42.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genmab A/S is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Genmab A/S is at $2.7B, which is lower that average. That is roughly 88.1% below the sector mean. Use the comparison chart on this page to see how GE9.F stacks up against individual peers as well.

Tracking GE9.F's ebit over time shows whether Genmab A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $2.7B That compares with $4.7B in the prior-year period — down 42.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Genmab A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $2.7B) with ownership activity and broader fundamentals.